Yeda Research and Develpment & Co. Ltd

Harvard College

Leland Stanford Junior University

The Weizmann Institute of Science

Yeda Research and Development Ltd.

Alcoholism and Drug Addition Research Foundation

Veda Research and Development Co., Ltd.

Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science

Ruth Arnon

Michael Sela

Dvora Teitelbaum

Eliezer Konfino

Tamar Ben-Yedidia

Rina Aharoni

Basak Kayhan

Sung-Ho Jeon

Raphael Levi

Jack L Strominger

Masha Fridkis-Hareli

Ruth Maron

Esther Hurvitz

Ben-Zion Dolitzky

Michal Eisenbach-Schwartz

Anton Frenkel

Meir Wilchek

Bilha Schechter

Adrian Gilbert

Jonathan Kipnis

Michal Schwartz

Gerald T Keusch

Oleg Butovsky

Yedy Israel

Arthur Donohue-Rolfe

Milka Linenberg

Michal Shapira

Chaim O Jacob

Gunhild Muller

Rivka Riven-Kreitmann

Ron Levy

Samario Chaitchik

Paul G Schlegel

Nelson J Chao

Ilana Harari

Irit Pinchasi

Noga Ron

Raya Eilam

Bashak Kayhan

Tamar Ben-Yedidya

Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.

Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Copolymer-1 improvements in compositions of copolymers

The present invention relates to the use of Copolymer 1 (glatiramer acetate), a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide, for the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.

Cop 1 for treatment of inflammatory bowel diseases

The present invention relates to influenza vaccines for human and veterinary use. In particular, the present invention provides a vaccine able to effect long term and cross-strain protection by including at least two influenza virus epitopes expressed as a chimeric polypeptide wherein at least one epitope is influenza A virus matrix protein epitope and the second epitope is a haemagglutinin peptide epitope.

Influenza vaccine

The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons. The invention also provides a method of treating a human subject afflicted with a neurodegenerative disease comprising administering to the human subject a therapeutically effective amount of any of the disclosed compositions so as to thereby treat the human subject.

Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases

A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually inflagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii) one T-helper hemagglutinin (HA) or nucleo-protein (NP) epitope that can bind to many HLA molecules; and (iii) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP) or matrix protein (M) epitopes that are restricted to the most prevalent HLA molecules in different human populations.

Peptide-based vaccine for influenza

The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.

Treatment of autoimmune conditions with Copolymer 1 and related Copolymers

The present invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.

Treatment of autoimmune conditions with copolymer 1 and related copolymers

Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D-Copolymer 1 when the disease being treated is graft-versus-host disease.

Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD

Growing community of inventors

Rehovot, Israel

Ruth Arnon